Abstract
The disposition of ketoconazole was characterized in the rat over a wide dose/concentration range. Bolus dose (0.03–10 mg/kg) studies indicate that plasma concentration–time profiles for ketoconazole are not superimposable when dose normalized because of nonlinearities occurring in both volume of distribution and clearance. The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated. From these results, infusion rates were calculated to maintain the plasma concentrations achieved with particular bolus doses. The curvilinear relationship between steady-state plasma concentration (0.015–8.3 mg/L) and ketoconazole infusion rate (0.021–2.45 mg/hr/kg) was analyzed in terms of Michaelis–Menten kinetics. A V max of 3.2 mg/hr/kg and K m of 2.1 mg/L were obtained by nonlinear regression analysis. At the end of the ketoconazole infusion, liver, adrenals and kidneys were removed and assayed for ketoconazole. Tissue-to-plasma partition coefficients for the liver and adrenals showed a marked dependence upon steady-state plasma concentration. Both parameters (liver, 22; and adrenals, 53) showed a decrease of approximately 10-fold as the plasma concentrations were increased. In contrast, the kidney:plasma partition coefficient (1.8), blood:plasma concentration ratio (0.6), and plasma binding (96%) of ketoconazole did not show a concentration dependence over the range studied. It is concluded that the liver is an important determinant of ketoconazole's volume of distribution and that saturation of this process accounts largely for the reduction in volume of distribution with increasing dose. The characterization of ketoconazole's hepatic clearance and binding in the rat helps resolve the apparent discrepancy between in vitro and in vivo observations on this azole's interaction with cytochrome P450.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
R. C. Heel, R. N. Brogan, A. Cormine, P. A. Morley, T. M. Speight, and G. S. Avery. Ketoconazole: A review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23:1–36 (1982).
Y. Yoshida and Y. Aoyama. Interaction of azole fungicides with yeast cytochrome P450 which catalyzes lanosterol 14α-demethylation. In In Vitro and in Vivo Evaluation of Antifungal Agents, K. Iawata and H. Van den Bossche (eds.), Elsevier, Amsterdam, 1986, pp. 123–134.
F. J. Holland, L. Fishman, J. D. Bailey, and A. T. A. Fazekas. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N. Engl. J. Med. 312:1023–1028 (1985).
J. Trachtenberg and A. Pont. Therapy for advanced prostate cancer. Lancet 2:433–435 (1984).
F. A. Shepherd, B. Hoffert, W. K. Evans, G. Embry, and J. Trachtenberg. Ketoconazole use in the treatment of ectopic adrenocorticotro hormone production and Cushing's syndrome in small-cell lung cancer. Arch. Intern. Med. 145:863–868 (1985).
J. J. Sheets and J. I. Mason. Ketoconazole—a potent inhibitor of cytochrome P450 dependent drug metabolism in rat liver. Drug Metab. Dispos. 12:603–606 (1984).
M. Pasanen, T. Taskinen, M. Iscon, E. A. Sotaniemi, M. Kairaluma, and O. Pelkonen. Inhibition of human hepatic and placental xenobiotic monooxygenases by imidazole antimycotics. Biochem. Pharmacol. 37:3861–3866 (1988).
K. Lavrijsen, J. Van Houdt, D. Thijs, W. Meuldermans, and J. Heykants. Interaction of miconazole, ketoconazole and itraconazole with rat liver microsomes. Xenobiotica 17:45–57 (1987).
P. Mosca, P. Bonzzi, G. Novelli, A. M. Jezequel, and F. Orlandi. In vitro inhibition of hepatic microsomal drug metabolism by ketoconazole. Br. J. Exp. Pathol. 66:737–742 (1985).
C. G. Meredith, A. L. Maldonado, and K. V. Speeg. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab. Dispos. 13:156–162 (1985).
J. B. Houston, M. J. Humphrey, D. E. Matthew, and M. H. Tarbit. Comparison of two azole antifungal drugs, ketoconazole and fluconazole, as modifiers of rat hepatic monooxygenase activity. Biochem. Pharmacol. 37:401–408 (1988).
R. G. Thompson, M. D. Rawlins, O. F. W. Jones, P. Wood, and F. M. Williams. The acute and subchronic effects of ketoconazole on hepatic microsomal monooxygenases in the rat. Biochem. Pharmacol. 37:3975–3980 (1988).
T. K. Daneshmend and D. W. Warnock. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokin. 14:13–34 (1988).
I. Shuster. The interaction of representative members from two classes of antimycotics—the azoles and the allylamines—with cytochrome P450 in steroidogenic tissues and liver. Xenobiotica 15:529–546 (1985).
Y. Yoshida and Y. Aoyoma. Interaction of azole antifungal agents with cytochrome P450-14DM purified from Saccharomyces Cerviseae microsomes. Biochem. Pharmacol. 36:229–235 (1987).
A. D. Rodrigues, D. F. V. Lewis, C. Ioannides, and D. V. Parke. Spectral and kinetic studies of the interaction of imidazole antifungal agents with micorsomal cytochromes P450. Xenobiotica 17:1315–1327 (1987).
A. D. Rodrigues, G. G. Gibson, C. Ioannides, and D. V. Parke. Interactions of imidazole antifungal agents with purified cytochrome P450 proteins. Biochem. Pharmacol. 24:4277–4281 (1987).
R. P. Remmel, K. Amoh, and M. M. Abdel-Monem. The disposition and pharmacokinetics of ketoconazole in the rat. Drug Metab. Dispos. 15:735–739 (1987).
J. G. Baxter, C. Brass, J. J. Schentag, and R. L. Slaughter. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J. Pharm. Sci. 75:443–447 (1986).
P. G. Harms and S. R. Ojeda. A rapid and simple procedure for chronic cannulation of the rat jugular vein. J. Appl. Physiol. 36:391–392 (1974).
C. M. Riley and M. O. James. Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography. J. Chromatogr. 377:287–294 (1986).
A. Adedoyin, L. Aarons, and J. B. Houston. Dose dependent pharmacokinetics of cimetidine in the rat. Xenobiotica 17:595–604 (1987).
H.-S. G. Chen and J. F. Gross. Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models. J. Pharmacokin. Biopharm. 7:117–125 (1979).
J. R. Gillette. Factors affecting drug metabolism. Ann. N.Y. Acad. Sci. 179:43–66 (1971).
E. W. Gascoigne, G. J. Barton, M. Michaels, W. Mueldermans, and J. Heykants. The kinetics of ketoconazole in animals and man. Clin. Res. Rev. 1:177–187 (1981).
K. S. Pang and J. R. Gillette. Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. Drug Metab. Dispos. 6:567–576 (1978).
G. M. Pollack, K. L. R. Browmer, H. B. Demby, and J. A. Jones. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose. Drug Metab. Dispos. 18:197–202 (1990).
Y.-C. Huang, J. L. Colaizzi, R. A. Bierman, R. Woestenborghs, and J. Heykants. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents. Chemother. 30:206–210 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matthew, D., Brennan, B., Zomorodi, K. et al. Disposition of Azole Antifungal Agents. I. Nonlinearities in Ketoconazole Clearance and Binding in Rat Liver. Pharm Res 10, 418–422 (1993). https://doi.org/10.1023/A:1018996524141
Issue Date:
DOI: https://doi.org/10.1023/A:1018996524141